DeLuca Richard R. 4

What Happened

• Richard R. DeLuca, Executive Vice President & President, Merck Animal Health, was granted two derivative awards on 2026-05-05 totaling 46,855 restricted stock units (11,931 + 34,924). The awards have a grant price of $0.00 (reported value $0 on grant), since these are compensation awards (RSUs) rather than open-market purchases.

Key Details

• Transaction date: 2026-05-05; Filing date: 2026-05-07 (filed within the Form 4 reporting window).
• Award amounts: 11,931 RSUs and 34,924 RSUs; total = 46,855 RSUs. Grant price reported $0.00.
• Shares owned after transaction: not disclosed in the provided excerpt of the filing.
• Footnotes: F1 — each restricted stock unit equals a contingent right to one share; F2 — these RSUs vest and will be distributed in three equal installments on 5/5/2027, 5/5/2028 and 5/5/2029; F3 — the filing also references an option vesting schedule (vesting in equal installments on the same dates).
• Timeliness: Filing appears timely (transaction on 5/5/2026; Form 4 filed 5/7/2026).

Context

• These are compensation grants (RSUs) that represent a contingent right to receive shares if and when they vest; no shares were purchased or sold at the time of grant. Such awards are common executive compensation and do not by themselves indicate insider buying or selling sentiment.